Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Department of Pharmaceutics, College of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq.
Oncol Res. 2024 Jun 20;32(7):1231-1237. doi: 10.32604/or.2024.047187. eCollection 2024.
Despite the availability of chemotherapy drugs such as 5-fluorouracil (5-FU), the treatment of some cancers such as gastric cancer remains challenging due to drug resistance and side effects. This study aimed to investigate the effect of celastrol in combination with the chemotherapy drug 5-FU on proliferation and induction of apoptosis in human gastric cancer cell lines (AGS and EPG85-257).
In this study, AGS and EPG85-257 cells were treated with different concentrations of celastrol, 5-FU, and their combination. Cell proliferation was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. The synergistic effect of 5-FU and celastrol was studied using Compusyn software. The DNA content at different phases of the cell cycle and apoptosis rate was measured using flow cytometry.
Co-treatment with low concentrations (10% inhibitory concentration (IC10)) of celastrol and 5-FU significantly reduced IC50 ( < 0.05) so that 48 h after treatment, IC50 was calculated at 3.77 and 6.9 μM for celastrol, 20.7 and 11.6 μM for 5-FU, and 5.03 and 4.57 μM for their combination for AGS and EPG85-257 cells, respectively. The mean percentage of apoptosis for AGS cells treated with celastrol, 5-FU, and their combination was obtained 23.9, 41.2, and 61.9, and for EPG85-257 cells 5.65, 46.9, and 55.7, respectively. In addition, the 5-FU and celastrol-5-FU combination induced cell cycle arrest in the synthesis phase.
Although celastrol could decrease the concentration of 5-fluorouracil that sufficed to suppress gastric cancer cells, additional studies are required to arrive at conclusive evidence on the anticancer effects of celastrol.
尽管有 5-氟尿嘧啶(5-FU)等化疗药物可用,但由于耐药性和副作用,某些癌症的治疗(如胃癌)仍然具有挑战性。本研究旨在探讨雷公藤红素与化疗药物 5-FU 联合应用对人胃癌细胞系(AGS 和 EPG85-257)增殖和诱导凋亡的影响。
在这项研究中,AGS 和 EPG85-257 细胞分别用不同浓度的雷公藤红素、5-FU 及其联合药物处理。用 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)法评估细胞增殖。用 Compusyn 软件研究 5-FU 和雷公藤红素的协同作用。用流式细胞术检测细胞周期各时相的 DNA 含量和凋亡率。
低浓度(10%抑制浓度(IC10))的雷公藤红素与 5-FU 联合治疗显著降低了 IC50(<0.05),因此,治疗后 48 小时,AGS 和 EPG85-257 细胞的 IC50 分别计算为 3.77 和 20.7 μM 为雷公藤红素,6.9 和 11.6 μM 为 5-FU,5.03 和 4.57 μM 为它们的组合。AGS 细胞用雷公藤红素、5-FU 和它们的组合处理的平均凋亡百分比分别为 23.9%、41.2%和 61.9%,EPG85-257 细胞分别为 5.65%、46.9%和 55.7%。此外,5-FU 和雷公藤红素-5-FU 联合诱导细胞周期停滞在合成期。
尽管雷公藤红素可以降低抑制胃癌细胞所需的 5-氟尿嘧啶浓度,但还需要进一步的研究来获得关于雷公藤红素抗癌作用的确凿证据。